ReviewNutrients2021
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.International journal of mental health nursing · 2025Pooled it
- Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.Molecular medicine (Cambridge, Mass.) · 2024Pooled it
- Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies.BMC medicine · 2026Review
- A person-centred and data-driven approach to phenotyping anorexia nervosa.Journal of eating disorders · 2026Article
- Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study.Health technology assessment (Winchester, England) · 2026Article
- Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).CNS drugs · 2026Review
- Anorexia nervosa: 150 years of critical theory.Journal of eating disorders · 2026Review
- Esketamine in depression: putative biomarkers from clinical research.European archives of psychiatry and clinical neuroscience · 2025Review
- Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.Journal of eating disorders · 2025Article
- [Pharmacotherapy of eating disorders-An update].Der Nervenarzt · 2025Review
- Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.Psychopharmacology bulletin · 2025Article
- Ketamine as adjuvant treatment in eating disorders: an exploratory study of a case series and retrospective analysis.Journal of eating disorders · 2025Article
- Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating.Therapeutic advances in psychopharmacology · 2025Article
- Pharmacotherapeutic strategies for the treatment of anorexia nervosa - novel targets to break a vicious cycle.Expert opinion on pharmacotherapy · 2024Review
- Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.BMC psychiatry · 2024Article
- Longitudinal changes in brain-derived neurotrophic factor (BDNF) but not cytokines contribute to hippocampal recovery in anorexia nervosa above increases in body mass index.Psychological medicine · 2024Article
- Care pathways for longstanding eating disorders must offer paths to recovery, not managed decline.BJPsych bulletin · 2024Article
- The multisensory mind: a systematic review of multisensory integration processing in Anorexia and Bulimia Nervosa.Journal of eating disorders · 2023Review
- Review
- Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa.Frontiers in psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) is a highly complex disorder to treat, especially in severe and enduring cases. Whilst the precise aetiology of the disorder is uncertain, malnutrition and weight loss can contribute to reductions in grey and white matter of the brain, impairments in neuroplasticity and neurogenesis and difficulties with cognitive flexibility, memory and learning. Depression is highly comorbid in AN and may be a barrier to recovery. However, traditional antidepressants are often ineffective in alleviating depressive symptoms in underweight patients with AN. There is an urgent need for new treatment approaches for AN. This review gives a conceptual overview for the treatment of AN with ketamine. Ketamine has rapid antidepressant effects, which are hypothesised to occur via increases in glutamate, with sequelae including increased neuroplasticity, neurogenesis and synaptogenesis. This article provides an overview of the use of ketamine for common psychiatric comorbidities of AN and discusses particular safety concerns and side effects. Potential avenues for future research and specific methodological considerations are explored. Overall, there appears to be ample theoretical background, via several potential mechanisms, that warrant the exploration of ketamine as a treatment for adults with AN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.